



US 20210341487A1

(19) **United States**(12) **Patent Application Publication**
Partridge et al.(10) **Pub. No.: US 2021/0341487 A1**(43) **Pub. Date: Nov. 4, 2021**(54) **NEUTRALIZING ANTIBODY ASSAY FOR THERAPEUTIC PROTEINS**

on Jun. 19, 2020, provisional application No. 63/172,488, filed on Apr. 8, 2021.

(71) Applicant: **Regeneron Pharmaceuticals, Inc.**,
Tarrytown, NY (US)(72) Inventors: **Michael Partridge**, Eastchester, NY (US); **Susan Irvin**, Thornwood, NY (US); **Manoj Rajadhyaksha**, Colchester, CT (US); **Aynur Hermann**, New York, NY (US)**Publication Classification**(51) **Int. Cl.****G01N 33/574** (2006.01)**G01N 33/50** (2006.01)(52) **U.S. Cl.**CPC ... **G01N 33/57492** (2013.01); **G01N 33/5023** (2013.01); **G01N 33/5041** (2013.01)(21) Appl. No.: **17/245,271**(22) Filed: **Apr. 30, 2021****Related U.S. Application Data**

(60) Provisional application No. 63/018,821, filed on May 1, 2020, provisional application No. 63/041,768, filed

(57)

ABSTRACT

The present invention generally pertains to methods of testing for the presence of neutralizing antibodies (NAbs) against therapeutic proteins. In particular, the present invention pertains to the use of mitigating agents against interfering competing drugs in ligand binding assays or cell-based assays for the detection of neutralizing antibodies against therapeutic proteins.

